Fig. 3: Cumulative incidence of ICANS in lymphoma patients treated with anti-CD19 CAR T cells. | Blood Cancer Journal

Fig. 3: Cumulative incidence of ICANS in lymphoma patients treated with anti-CD19 CAR T cells.

From: Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma

Fig. 3

Time to grade ≥2 ICANS (A) and grade ≥3 ICANS (B) were estimated. Patients were stratified by whether they received prophylactic G-CSF (N = 140) or not (control, N = 57), and compared using the method of Gray. There was no significant difference in the cumulative incidence of grade ≥2 and grade 3 ICANS between the prophylactic G-CSF and control groups, including in a multivariate analysis (see Table 5). 95% confidence intervals are represented by shading.

Back to article page